Your browser doesn't support javascript.
loading
Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial.
Hamzavi, Iltefat; Rosmarin, David; Harris, John E; Pandya, Amit G; Lebwohl, Mark; Gottlieb, Alice B; Butler, Kathleen; Kuo, Fiona I; Sun, Kang; Grimes, Pearl.
Affiliation
  • Hamzavi I; Henry Ford Medical Center, Detroit, Michigan. Electronic address: IHamzavi@hamzavi.com.
  • Rosmarin D; Tufts Medical Center, Boston, Massachusetts.
  • Harris JE; University of Massachusetts Medical School, Worcester, Massachusetts.
  • Pandya AG; Palo Alto Foundation Medical Group, Mountain View, California; University of Texas Southwestern Medical Center, Dallas, Texas.
  • Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Gottlieb AB; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Butler K; Incyte Corporation, Wilmington, Delaware.
  • Kuo FI; Incyte Corporation, Wilmington, Delaware.
  • Sun K; Incyte Corporation, Wilmington, Delaware.
  • Grimes P; The Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California.
J Am Acad Dermatol ; 86(6): 1398-1401, 2022 06.
Article in En | MEDLINE | ID: mdl-34089797
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Vitiligo Type of study: Clinical_trials Limits: Humans Language: En Journal: J Am Acad Dermatol Year: 2022 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Vitiligo Type of study: Clinical_trials Limits: Humans Language: En Journal: J Am Acad Dermatol Year: 2022 Type: Article